Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00275652 | A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. | PHASE3 | COMPLETED | 6 | — | — | Jun 1, 2004 | Aug 1, 2007 | Mar 23, 2011 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| LdT (Telbivudine) and lamivudine | DRUG | - |
Patients with chronic hepatitis b with evidence of cirrhosis, who are at least 18 to 70 years old, may be eligible to participate in this study.